Reply: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details

Hepatology. 2025 May 9. doi: 10.1097/HEP.0000000000001395. Online ahead of print.

Da-Long Yang¹, Yi-Fan Li¹, Yao-Jie Li¹, Guo-Gao Qiu¹, Zhi-Dong Liu¹, Yi-Ge Zhang¹, Huan Chen¹, Jian-Hong Zhong^{1

2

3}

¹ Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.
² Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumors (Guangxi Medical University), Ministry of Education, Nanning, China.
³ Guangxi Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumors, Nanning, China.

No abstract available